Development of a genetic priority score to predict drug side effects using human genetic evidence

Abstract Many drug failures in clinical trials are due to inadequate safety profiles. We developed an in-silico side effect genetic priority score (SE-GPS) that leverages human genetic evidence to inform side effect risk for a given drug target. We construct the SE-GPS in the Open Target dataset usi...

詳細記述

書誌詳細

出版年:	Nature Communications
主要な著者:	Áine Duffy, Robert Chen, David Stein, Joshua K. Park, Matthew Mort, Marie Verbanck, Avner Schlessinger, Yuval Itan, David N. Cooper, Daniel M. Jordan, Ghislain Rocheleau, Ron Do
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2025-09-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-025-63762-y